Trial Profile
Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Carboplatin; Cytarabine; Dexamethasone; Etoposide; Ifosfamide
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms O-ICE
- 24 Oct 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 27 Sep 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 27 Sep 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.